Logo image of UPC

UNIVERSE PHARMACEUTICALS INC (UPC) Stock Fundamental Analysis

USA - NASDAQ:UPC - KYG9442G1385 - Common Stock

5 USD
-0.18 (-3.55%)
Last: 10/24/2025, 8:00:22 PM
4.91 USD
-0.09 (-1.8%)
After Hours: 10/24/2025, 8:00:22 PM
Fundamental Rating

3

Overall UPC gets a fundamental rating of 3 out of 10. We evaluated UPC against 192 industry peers in the Pharmaceuticals industry. UPC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UPC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year UPC was profitable.
In the past year UPC has reported a negative cash flow from operations.
In multiple years UPC reported negative net income over the last 5 years.
In multiple years UPC reported negative operating cash flow during the last 5 years.
UPC Yearly Net Income VS EBIT VS OCF VS FCFUPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

1.2 Ratios

Looking at the Return On Assets, with a value of 1.35%, UPC belongs to the top of the industry, outperforming 82.72% of the companies in the same industry.
UPC has a better Return On Equity (1.97%) than 82.20% of its industry peers.
Industry RankSector Rank
ROA 1.35%
ROE 1.97%
ROIC N/A
ROA(3y)-14.43%
ROA(5y)-0.18%
ROE(3y)-20.51%
ROE(5y)-1.19%
ROIC(3y)N/A
ROIC(5y)N/A
UPC Yearly ROA, ROE, ROICUPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

Looking at the Profit Margin, with a value of 5.65%, UPC belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
UPC has a Gross Margin (30.41%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of UPC has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 5.65%
GM 30.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.65%
GM growth 5Y-8.51%
UPC Yearly Profit, Operating, Gross MarginsUPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

4

2. Health

2.1 Basic Checks

UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UPC has more shares outstanding
UPC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, UPC has an improved debt to assets ratio.
UPC Yearly Shares OutstandingUPC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
UPC Yearly Total Debt VS Total AssetsUPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

UPC has an Altman-Z score of 0.38. This is a bad value and indicates that UPC is not financially healthy and even has some risk of bankruptcy.
UPC has a Altman-Z score (0.38) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.04 indicates that UPC is not too dependend on debt financing.
UPC has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACCN/A
WACC6.78%
UPC Yearly LT Debt VS Equity VS FCFUPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

UPC has a Current Ratio of 2.78. This indicates that UPC is financially healthy and has no problem in meeting its short term obligations.
UPC has a Current ratio of 2.78. This is comparable to the rest of the industry: UPC outperforms 52.88% of its industry peers.
A Quick Ratio of 2.62 indicates that UPC has no problem at all paying its short term obligations.
UPC's Quick ratio of 2.62 is in line compared to the rest of the industry. UPC outperforms 54.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.62
UPC Yearly Current Assets VS Current LiabilitesUPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

UPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.13%, which is quite impressive.
UPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.81%.
The Revenue has been decreasing by -7.08% on average over the past years.
EPS 1Y (TTM)106.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.56%
Revenue 1Y (TTM)-27.81%
Revenue growth 3Y-21.71%
Revenue growth 5Y-7.08%
Sales Q2Q%-28.96%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UPC Yearly Revenue VS EstimatesUPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

UPC is valuated cheaply with a Price/Earnings ratio of 0.03.
Compared to the rest of the industry, the Price/Earnings ratio of UPC indicates a rather cheap valuation: UPC is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of UPC to the average of the S&P500 Index (26.91), we can say UPC is valued rather cheaply.
Industry RankSector Rank
PE 0.03
Fwd PE N/A
UPC Price Earnings VS Forward Price EarningsUPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPC Per share dataUPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100 150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UPC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIVERSE PHARMACEUTICALS INC

NASDAQ:UPC (10/24/2025, 8:00:22 PM)

After market: 4.91 -0.09 (-1.8%)

5

-0.18 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2022-02-11/dmh
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.80M
Revenue(TTM)19.29M
Net Income(TTM)1.09M
Analysts0
Price TargetN/A
Short Float %6.45%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.03
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)191.57
EY3831.4%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-21.51
FCFYN/A
OCF(TTM)-20.76
OCFYN/A
SpS34.45
BVpS98.54
TBVpS98.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number651.74
Profitability
Industry RankSector Rank
ROA 1.35%
ROE 1.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 5.65%
GM 30.41%
FCFM N/A
ROA(3y)-14.43%
ROA(5y)-0.18%
ROE(3y)-20.51%
ROE(5y)-1.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.65%
GM growth 5Y-8.51%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.09%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.62
Altman-Z 0.38
F-Score5
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)30.9%
Cap/Depr(5y)40.54%
Cap/Sales(3y)0.59%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.81%
Revenue growth 3Y-21.71%
Revenue growth 5Y-7.08%
Sales Q2Q%-28.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-352.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-342.11%
OCF growth 3YN/A
OCF growth 5YN/A

UNIVERSE PHARMACEUTICALS INC / UPC FAQ

What is the ChartMill fundamental rating of UNIVERSE PHARMACEUTICALS INC (UPC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to UPC.


What is the valuation status of UNIVERSE PHARMACEUTICALS INC (UPC) stock?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSE PHARMACEUTICALS INC (UPC). This can be considered as Overvalued.


How profitable is UNIVERSE PHARMACEUTICALS INC (UPC) stock?

UNIVERSE PHARMACEUTICALS INC (UPC) has a profitability rating of 3 / 10.


What are the PE and PB ratios of UNIVERSE PHARMACEUTICALS INC (UPC) stock?

The Price/Earnings (PE) ratio for UNIVERSE PHARMACEUTICALS INC (UPC) is 0.03 and the Price/Book (PB) ratio is 0.05.